X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse Sun Pharma with MYLAN INC. - US - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SUN PHARMA vs MYLAN (US) - Comparison Results

SUN PHARMA    Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

MYLAN (US)
   Change

Mylan is one of the world’s leading generics and specialty pharmaceutical company. Its products span to customers in about 140 countries across the world. The company maintains one of the industry’s broadest and highest quality product portfolios, wh... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 SUN PHARMA   MYLAN
EQUITY SHARE DATA
    SUN PHARMA
Mar-18
MYLAN
Dec-14
SUN PHARMA/
MYLAN
5-Yr Chart
Click to enlarge
High Rs7014,238-   
Low Rs4332,986-   
Sales per share (Unadj.) Rs110.41,450.7-  
Earnings per share (Unadj.) Rs11.0174.8-  
Cash flow per share (Unadj.) Rs17.2281.3-  
Dividends per share (Unadj.) Rs2.000-  
Dividend yield (eoy) %0.40-  
Book value per share (Unadj.) Rs158.8721.1-  
Shares outstanding (eoy) m2,399.26378.37-   
Bonus/Rights/Conversions -OI-  
Price / Sales ratio x5.12.5 206.2%   
Avg P/E ratio x51.620.7 249.8%  
P/CF ratio (eoy) x32.912.8 256.2%  
Price / Book Value ratio x3.65.0 71.3%  
Dividend payout %18.20-   
Avg Mkt Cap Rs m1,360,0211,366,627 99.5%   
No. of employees `00017.825.0 71.2%   
Total wages/salary Rs m53,6710-   
Avg. sales/employee Rs Th14,890.921,955.7 67.8%   
Avg. wages/employee Rs Th3,017.10-   
Avg. net profit/employee Rs Th1,480.62,644.9 56.0%   
INCOME DATA
Net Sales Rs m264,895548,892 48.3%  
Other income Rs m8,388-3,200 -262.2%   
Total revenues Rs m273,282545,693 50.1%   
Gross profit Rs m56,081136,512 41.1%  
Depreciation Rs m14,99840,314 37.2%   
Interest Rs m5,17623,676 21.9%   
Profit before tax Rs m44,29569,323 63.9%   
Minority Interest Rs m0-284 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-9,5050-   
Tax Rs m8,4522,915 289.9%   
Profit after tax Rs m26,33866,123 39.8%  
Gross profit margin %21.224.9 85.1%  
Effective tax rate %19.14.2 453.8%   
Net profit margin %9.912.0 82.5%  
BALANCE SHEET DATA
Current assets Rs m316,359482,549 65.6%   
Current liabilities Rs m198,643377,257 52.7%   
Net working cap to sales %44.419.2 231.7%  
Current ratio x1.61.3 124.5%  
Inventory Days Days9578 121.5%  
Debtors Days Days108107 100.4%  
Net fixed assets Rs m213,178126,985 167.9%   
Share capital Rs m2,39919,410 12.4%   
"Free" reserves Rs m378,6060-   
Net worth Rs m381,006272,853 139.6%   
Long term debt Rs m17,721407,616 4.3%   
Total assets Rs m643,0281,099,028 58.5%  
Interest coverage x9.63.9 243.3%   
Debt to equity ratio x01.5 3.1%  
Sales to assets ratio x0.40.5 82.5%   
Return on assets %4.98.2 60.0%  
Return on equity %6.924.2 28.5%  
Return on capital %10.013.6 73.6%  
Exports to sales %00-   
Imports to sales %00-   
Net fx Rs m10,6730-   
CASH FLOW
From Operations Rs m39,07272,152 54.2%  
From Investments Rs m-33,708-56,901 59.2%  
From Financial Activity Rs m-15,393-19,012 81.0%  
Net Cashflow Rs m-7,359-3,761 195.7%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for MYLAN (US) is United States Dollars. All data has been converted at 71.1 Rs / USD

Compare SUN PHARMA With: ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  

Compare SUN PHARMA With: UNICHEM LAB  STRIDES PHARMA SCIENCE  ABBOTT INDIA  STERLING BIOTECH  AJANTA PHARMA  



Today's Market

Recapitalisation Package for PSBs: The Pros & Cons(Podcast)

Corporate governance issues with certain companies, uncertainty surrounding national elections and global issues like trade wars, Brexit, have taken a toll on the Indian markets.

Related Views On News

SUN PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 265.5% (Quarterly Result Update)

Feb 13, 2019 | Updated on Feb 13, 2019

For the quarter ended December 2018, SUN PHARMA has posted a net profit of Rs 15 bn (up 265.5% YoY). Sales on the other hand came in at Rs 77 bn (up 16.3% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

SUN PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Dec 20, 2018 | Updated on Dec 20, 2018

Here's an analysis of the annual report of SUN PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of SUN PHARMA. Also includes updates on the valuation of SUN PHARMA.

SUN PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 110.7% (Quarterly Result Update)

Nov 14, 2018 | Updated on Nov 14, 2018

For the quarter ended September 2018, SUN PHARMA has posted a net profit of Rs 1 bn (down 110.7% YoY). Sales on the other hand came in at Rs 69 bn (up 4.3% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

More Views on News

Most Popular

The One Real Estate Stock to Buy Now(The 5 Minute Wrapup)

Feb 13, 2019

The real estate sector is ready to make a comeback. This is the stock to consider buying.

Don't Be Afraid of the Market; Buy Stocks Like This One(The 5 Minute Wrapup)

Feb 14, 2019

During this tough period in the market, a contrarian approach holds huge potential upside for this Smart Money Secrets stock.

Small Caps Under Seige: Could This Be A Once-in-a-Decade Wealth Creating Opportunity?(Profit Hunter)

Feb 14, 2019

Don't let the dark clouds hovering over small caps scare you into hiding; it will rain gold as sentiments recover. Indeed, there is a blood bath. And if you are a first time investor, the correction is deep enough to scare you out of markets.

The 4-Point Plan to Accelerate India to a 10 Trillion Dollar Economy(The 5 Minute Wrapup)

Feb 12, 2019

Two questions I have been eagerly waiting to ask you ever since Budget 2019 was announced.

The Train to 'Small-Cap-Profits Land' is Back on the Station!(Profit Hunter)

Feb 15, 2019

Why its great news that prices for small caps over the last few days have been falling like there's no tomorrow.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

SUN PHARMA SHARE PRICE


Feb 22, 2019 (Close)

TRACK SUN PHARMA

  • Track your investment in SUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SUN PHARMA - DR. REDDYS LAB COMPARISON

COMPARE SUN PHARMA WITH

MARKET STATS